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ABSTRACT OF THE DISSERTATION
Ultrasound-guided Optical Techniques for Cancer Diagnosis: System and Algorithm
Development
By
Atahar Kamal Mostafa
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, May, 2019
Dr. Quing Zhu, Chair
Worldwide, breast cancer is the most common cancer among women. In the United States alone,
the American cancer society has estimated that there will be 271,270 new breast cancer cases in
2019, and 42,260 lives will be lost to the disease. Ultrasound (US), mammography, and magnetic
resonance imaging (MRI) are regularly used for breast cancer diagnosis and therapy monitoring.
However, they sometimes fail to diagnose breast cancer effectively. These shortcomings have
motivated researchers to explore new modalities. One of these modalities, diffuse optical
tomography (DOT), utilizes near-infrared (NIR) light to reveal the optical properties of tissue.
NIR-based DOT images the contrast between a suspected lesion’s location and the background
tissue, caused by the higher NIR absorption of the hemoglobin, which characterizes tumors. The
limitation of high light scattering inside tissue is minimized by using ultrasound image to find the
tumor location.
This thesis focuses on developing a compact, low-cost ultrasound guided diffuse optical
tomography imaging system and on improving optical image reconstruction by extracting the
tumor’s location and size from co-registered ultrasound images. Several electronic components
have been redesigned and optimized to save space and cost and to improve the user experience. In

xi

terms of software and algorithm development, manual extraction of tumor information from
ultrasound images has been replaced by using a semi-automated ultrasound image segmentation
algorithm that reduces the optical image reconstruction time and operator dependency. This system
and algorithm have been validated with phantom and clinical data and have demonstrated their
efficacy. An ongoing clinical trial will continue to gather more patient data to improve the
robustness of the imaging algorithm.
Another part of this research focuses on ovarian cancer diagnosis. Ovarian cancer is the most
deadly of all gynecological cancers, with a less than 50% five-year survival rate. This cancer can
evolve without any noticeable symptom, which makes it difficult to diagnose in an early stage.
Although ultrasound-guided photoacoustic tomography (PAT) has demonstrated potential for
early detection of ovarian cancer, clinical studies have been very limited due to the lack of robust
PAT systems.
In this research, we have customized a commercial ultrasound system to obtain real-time coregistered PAT and US images. This system was validated with several phantom studies before
use in a clinical trial. PAT and US raw data from 16 ovarian cancer patients was used to extract
spectral features for training and testing classifiers for automatic diagnosis. For some challenging
cases, the region of interest selection was improved by reconstructing co-registered Doppler
images. This study will be continued in order to obtain quantitative tissue properties using USguided PAT.

xii

1 Introduction to Cancer Imaging
1.1 Introduction
In modern medical practice, imaging is essential in diagnosing disease and monitoring treatment
response. Ultrasound, MRI, X-ray, and nuclear imaging are frequently used in hospital settings
to image properties of the human body that are related to disease. All of these modalities use
different methods to monitor the physical or functional properties of tissue. Ultrasound employs
high-frequency sound waves to image mechanical properties. MRI captures the spin of tissue
molecules to provide functional information. X-ray imaging exploits different degrees of energy
absorption to show the contrast among different tissues. Several categories of nuclear imaging
use radiative contrast agents to observe the functionality of a particular organ. Although each of
these imaging techniques has its particular strengths and drawbacks, singly and collectively they
are widely used for cancer diagnosis and treatment monitoring.

In recent decades, optical imaging techniques in particular have become widely used for medical
research and preclinical and clinical evaluations. Several optical imaging modalities, for example,
optical coherence tomography, endoscopy, and spectroscopy, have become popular tools in the
standard point of care. For cancer imaging, physicians and researchers take advantage of the highresolution imaging capabilities of optical imaging. Diffuse optical tomography uses the light
absorption of hemoglobin to provide a contrast between the background and cancer regions. It
has already demonstrated considerable potential in cancer diagnosis and treatment monitoring.
Photoacoustic tomography, another optical imaging technology which uses the light absorption
of hemoglobin, combines its information with the physics of ultrasound propagation to obtain
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both the mechanical and functional properties of the target tissue. This thesis discusses
ultrasound-guided diffuse optical tomography and photoacoustic tomography and their
applications in cancer imaging. It is organized into the following four chapters.

The reminder of this chapter briefly reviews medical imaging technologies, as well as diagnosis
and treatment monitoring for breast and ovarian cancers.
Chapter 2 discusses the theory and application of ultrasound-guided diffuse optical tomography
for breast cancer diagnosis, along with the system development and algorithm improvement for
this technology.
Chapter 3 focuses on photoacoustic tomography, and includes the system’s development and
algorithms for diagnosis of ovarian cancer
Chapter 4 summarizes the above three chapters and discusses several remaining challenges at the
frontiers of ultrasound-guided diffuse optical tomography and photoacoustic tomography.

1.2 Popular Medical Imaging Techniques
The ability to image the internal organs of the human body started with the discovery of the Xray by Wilhelm Röntgen in 1895[1]. The absorption variations of X-ray energy in different tissues
create contrast in an X-ray image, enabling the non-invasive imaging of human organs. Since its
invention, X-ray imaging has proved a very reliable way to examine bones and diagnose diseases.
Computed tomography (CT) is an advanced version of X-ray imaging in which a 3-D image is
generated using multiple sources and detectors around the subject. Different contrast agents can
also be used to increase the contrast among different tissues.
Ultrasound imaging gained popularity for medical applications in the late 1950s [2]. Highfrequency sound waves are transmitted into the human body, and the reflected waves from tissue
2

boundaries are recorded using an ultrasound transducer for later processing and image
reconstruction. Used mainly to image the mechanical properties of tissue, ultrasound imaging
provides a low-cost and versatile means to examine internal organs. Ultrasound is non-invasive,
does not require any contrast agent, and, when used prudently, does not have any adverse effect
on the patient’s body. Doppler imaging and elastography are variants of ultrasound imaging that
examine different mechanical properties of organs and tissues.

MRI was developed in the last century after Raymond Damadian discovered the difference in the
magnetic relaxation times of different tissues. In MRI, the subject is placed in a strong magnetic
field and the spins of the molecules inside the tissue are aligned with the direction of the applied
magnetic field. When the excitation is removed, the molecules release the absorbed energy at
different rates, depending on their properties. The resulting contrast between different soft tissues
provides very high resolution images that are suitable for cancer diagnosis[3].

Optical imaging, the most common form of medical imaging technology, is widely used in disease
diagnosis, prevention, and treatment[4]. Endoscopy, optical coherence tomography,
photoacoustic imaging, diffuse optical imaging, and spectroscopy are a few examples of medical
optical imaging that have been developed in the last few decades. In the field of optical
tomography, which is the focus of this dissertation, researchers have been advancing different
techniques for the last two decades. Like ultrasound and X-ray, optical tomography provides a
non-invasive means to examine the functionality of human organs and tissues. It uses the visible
spectrum of electromagnetic waves and is implemented a wide variety of imaging techniques.
Some optical imaging techniques are often combined with conventional imaging modalities to
improve the performance of both imaging techniques.
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1.3 Breast Cancer
Although breast cancer starts with a breast tumor, which presents as a lump inside the breast, not
all breast lumps are life-threatening. The breast is a complex structure of fat, ducts, lobules, and
stroma on top of the chest wall muscle. Still, any lump detected in the breast could be a possible
life-threatening cancer. In the case of malignant tumors, cancer cells create abnormal breast lumps
and, at a later stage, spread to other parts of the body through the ducts and bloodstream, in a
process called metastasis. In metastasis stage, breast cancer becomes deadly. According to the
National Breast Cancer Foundation, one in eight women will be diagnosed with breast cancer in
their lifetime, making this the most common form of cancer among women [5]. It is estimated that
every year more than 250,000 women are diagnosed with breast cancer and more than 40,000 die
from it. So, early diagnosis and treatment are important to cure breast cancer and save lives [6].

Aggressive cell growth inside the breast causes malignant tumors. During tumor development,
new micro blood vessels grow near the tumor zone to supply nutrition to the growing tissues, in a
process called angiogenesis [7]. Because of angiogenesis, a malignant tumor site usually contains
more hemoglobin than the surrounding tissue. However, in benign breast tumors the hemoglobin
concentration is much lower because benign tumors are usually fluid-filled cysts or inflammations
of lobules, mammary ducts, and stroma. Thus, they contain fewer microvessels than malignant
tumors, and this difference can be utilized in breast cancer diagnosis using optical imaging
modalities.
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1.3.1 Breast Cancer Diagnosis and Treatment Monitoring
For breast cancer diagnosis and treatment monitoring, different imaging methods have been
employed, including mammography, ultrasound imaging (US), and magnetic resonance imaging
(MRI). Mammography is the most commonly used method for breast cancer diagnosis. However,
in dense breasts it has relatively low sensitivity in early cancer diagnosis [3]. US provides better
results than mammography but still provides many false positives and results in many unnecessary
biopsies [8]. MRI has superior sensitivity in breast cancer detection and diagnosis, but its high cost
makes it less useful for continuous treatment monitoring [9]. Dynamic contrast-enhanced MRI and
positron emission tomography (PET) are very successful in treatment monitoring and have
demonstrated their efficacy in early identification of breast cancer patients who are not responding
to chemotherapy, but their equipment is expensive and they require the injection of contrast agents,
which prevents them from being used repeatedly for monitoring patients during treatment[10][11].

Diffuse optical tomography (DOT) is a noninvasive imaging technique that uses near-infrared
(NIR) light to assess the optical properties of tissue. NIR light has minimum absorption in water,
so this technique can image up to 4 cm deep tissue in reflection geometry. The NIR wavelength
range (∼700 to 900 nm) is also optimally sensitive to both oxygenated and deoxygenated
hemoglobin, which are two main chromophores of blood[12]. The hemoglobin concentration of
tissue is related to angiogenesis, thus imaging the hemoglobin concentration provides useful
information for breast cancer diagnosis. DOT has shown promising results in assessing breast
cancer because of its sensitivity to oxygenated and deoxygenated hemoglobin [13]. Moreover,
DOT also has demonstrated great potential in the assessment of tumor vasculature response to
neoadjuvant chemotherapy [14]. DOT systems are portable, low cost, and require no contrast
5

agents, which make them an ideal alternative to currently used modalities for breast cancer
diagnosis and monitoring in clinical settings.

1.4 Ovarian Cancer
Ovarian cancer has the lowest 5-year survival rate (50% or less) of all the gynecologic cancers [6].
Because of the high mortality associated with ovarian cancer, most women screened with an
ovarian abnormality will undergo oophorectomy, even though they have at most a 2% risk of
having ovarian cancer [15]. With the current screening and diagnostic abilities, most women (70%)
with ovarian cancer will be diagnosed at Stage III or IV (widespread intra-abdominal disease),
where the 5-year survival rate is less than 30%. By contrast, Stage I cancers have a 5-year survival
rate of 80-90%. Hereditary ovarian cancer is diagnosed approximately 7-14 years earlier than
cancer caused by sporadic mutations [16][17], which increases the potential cost/benefit ratio of
its early diagnosis. Technology capable of reliably diagnosing ovarian cancer in earlier stages or
prior to the development of invasive disease could reduce the high mortality and the large
economic impact of this disease, particularly in high-risk women. Perhaps an even larger benefit
would be that many women could avoid surgery because they could be assured that an ovarian
mass was not cancer.

1.4.1 Ovarian Cancer Diagnosis
Because ovarian cancer lacks reliable symptoms and efficacious screening techniques, it is
predominantly diagnosed in Stages III and IV. Currently, there is no single test for ovarian cancer,
and the combination of serum marker CA125 screening (sensitivity of <50% [18],[19]),
transvaginal ultrasound (US) (3.1% positive predictive value [20]), and pelvic exams (sensitivity
of only 30%) yields low positive predictive value. CT scans have been studied extensively for
6

ovarian cancer detection, and multiple studies confirm that CT has a sensitivity of 45%, a
specificity of 85%, a positive predictive value of 80%, and a negative predictive value of 50%.
However, it is poor in the detection of metastases of < 2 cm. [21]. A 2003 publication [22]
suggested that MRI was superior to CT for characterizing malignant features of an ovarian mass,
and MRI is often used when US is not diagnostic. However, MRI is costly and typically used as
a secondary imaging method. Positron emission tomography (PET), using 18F-FDG as a tracer,
can detect malignant cancers with altered glucose metabolism and has been used for the assessment
of lymph node involvement [23], evaluation of pretreatment staging, and treatment response and
detection of cancer metastases. However, it has limited value in lesion localization in early stages
of ovarian cancer because of the difficulty in distinguishing between the signal from early-stage
cancers and the background uptake signals coming from the normal tissue [24]. Thus, we still
need better techniques to interrogate the ovary and rule out cancer.

Photoacoustic tomography (PAT) is an emerging technique in which a short-pulsed laser beam
penetrates diffusively into a tissue sample [25]. Transient acoustic waves, or photoacoustic waves,
arise from thermoelastic expansion resulting from a transient temperature rise (on the order of
10mK), and are then measured around the sample by US transducers. The acquired photoacoustic
waves are used to reconstruct, at ultrasound resolution, the optical absorption distribution, which
reveals optical contrast that is directly related to the microvessel density of tumors or tumor
angiogenesis [7]. If two optical wavelengths are used, photoacoustic waves can be used to
reconstruct the distribution of tumor hypoxia, which is an important indicator of tumor metabolism
and therapeutic response. These functional parameters are critical in the initial diagnosis of a
tumor and the assessment of tumor response to treatment. Due to intense light scattering in tissue,
to date, pure optical methods require direct contact with the ovary, which necessitates an invasive
7

access procedure [26]. Photoacoustic techniques minimize the deleterious effects of intense light
scattering by measuring ultrasonic waves generated from the ovarian tissue; they, therefore, have
great potential to non-invasively reveal tumor functional information. The penetration depth of
PAT is scalable with ultrasound frequency. In the diagnostic frequency range of 3 to 8 MHz, the
penetration depth in tissue can reach 4-5 cm using NIR light [27], which is comparable with the
penetration depth used in conventional transvaginal US. Several studies have proven that
photoacoustic imaging could be an effective tool for the early diagnosis of ovarian cancer [28].
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2 Ultrasound Guided Diffuse Optical
Tomography
2.1 Diffuse Optical Tomography
Diffuse optical tomography (DOT) is a noninvasive technique which uses near-infrared (NIR) light
to image optical properties of tissue. Due to the low water absorption in the NIR spectrum, the
light can penetrate several centimeters inside soft tissue, i.e., breast and brain. Reflected or
transmitted light measured at the tissue surface is used to reconstruct tomographic images[1][2].
DOT has demonstrated huge potential in cancer diagnosis and treatment monitoring by mapping
hemoglobin concentration, which is related to vasculature content and tumor angiogenesis. It is
possible to measure oxygenated, deoxygenated and total hemoglobin concentrations using
multiple wavelengths. It also provides information regarding oxygen saturation, lipid and water
concentration. These measurements could be effectively used to diagnose cancers vs. benign
lesions and monitor treatment response because malignant tumors typically have higher
hemoglobin content as compared to benign lesions and the hemoglobin changes differ between
treatment responders and non-responders [3]–[7].
Diffuse optical tomography can be classified into three categories based on the type of source
signal. They are: time domain, frequency domain, and direct current diffuse optical tomography
[8]. Time domain DOT uses short light pulses and records the broadened reemitted signal.
Amplitude modulated light is used as a source in frequency domain DOT and reemitted signal has
reduced modulation depth. Carrier signal usually has several hundreds of MHz frequency for
frequency domain DOT. Direct current or continuous wave DOT uses a fixed amplitude light
source, which may be modulated with low-frequency carriers to improve noise performance. Time
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domain DOT provides the most information; however, it requires an expensive detector and longer
data acquisition time. Continuous wave DOT is low-cost but provides less information compared
to the other two categories. Frequency domain DOT has optimum cost and performance in
providing useful information, which makes it the popular choice among researchers who are
working in the DOT domain.
DOT suffers from intensive light scattering inside the tissue and scattering causes uncertainty in
reconstructed target location and inaccuracy of target quantification. These problems can be
largely overcome by using other imaging techniques to guide the DOT for localization and
reconstruction. US, Mammography, MRI guided DOT [7][9][10] have been investigated for
various applications with a promising outcome. US-guided DOT has been developed by our group,
and its utility in cancer diagnosis and treatment monitoring has demonstrated from several clinical
studies [7][11].

2.2 Ultrasound-guided DOT
In the US-guided DOT approach, co-registered US images are captured and size and depth
information of the tumor has to be incorporated in DOT reconstruction as a Region of Interest
(ROI). A dual-zone mesh image reconstruction [12] is used to segment the ROI and background
region with finer and coarse mesh sizes respectively. This scheme effectively reduces the total
number of voxels with unknown optical absorption for imaging reconstruction, which is an
underdetermined problem. Additionally, the total absorption of each voxel is reconstructed and
divided by the voxel size to provide accurate absorption distributions. Since lesion absorption is
higher than background in general, the total absorption, which is the product of voxel size and
lesion absorption, of a lesion in a smaller voxel is about the same scale of total absorption of
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background in a larger voxel. Therefore, the inversion is well-conditioned and converges in fewer
iterations.
Absorption map of each wavelength was reconstructed using the dual-mesh approach with lesion
parameters obtained from the co-registered US. Because the spatial resolution of diffused light is
weaker than that of US, the ROI is chosen to be at least two to three times larger than that seen by
using US in x-y dimensions. In addition, because the depth localization of diffused light is very
poor, a tighter ROI in the depth dimension is set using the co-registered US. The weight matrix
was computed using the fitted optical properties of each patient’s normal contralateral breast. The
scattered field Usd measured from the lesion area was related to the internal absorption coefficients
∆µa using the following equation:
[𝑈𝑠𝑑 ]𝑚×1 = [𝑊𝐿 , 𝑊𝐵 ]𝑚×𝑁 [𝑀𝐿 , 𝑀𝐵 ]𝑇 𝑁×1
Where 𝑚 = 𝑠 × 𝑑 the total number of source-detector pairs, WL, WB are the weight matrix for
lesion and background regions respectively. ML and MB are the total absorption of the lesion and
background respectively; can be expressed using the following two equations:

[𝑀𝐿 ] = [ ∫ ∆𝜇𝑎𝜆 (𝑟 ′ )𝑑 3 𝑟 ′ , … … . ∫ ∆𝜇𝑎𝜆 (𝑟 ′ )𝑑3 𝑟 ′ ,]
1𝐿

𝑁𝐿

And

[𝑀𝐵 ] = [ ∫ ∆𝜇𝑎𝜆 (𝑟 ′ )𝑑 3 𝑟 ′ , … … . ∫ ∆𝜇𝑎𝜆 (𝑟 ′ )𝑑 3 𝑟 ′ ,]
1𝐵

𝑁𝐵
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To obtain the unknown absorption information, the conjugate gradient method was used to solve
the inverse problem formulated as minimize ‖𝑈𝑠𝑑 − 𝑊𝑀‖2 , where ‖. ‖ is the Euclidean norm.
Since this is an ill-posed problem due to the limited source and detection pairs and correlated
diffused scattering field, the dual mesh technique utilizes the tumor location and size information
extracted from co-registered US images for reconstruction to partially resolve this problem [12].
In our US-guided DOT, we are using four wavelengths that gives us the ability to estimate
oxygenated (oxyHb) and deoxygeneated hemoglobin (deoxyHb) in the tumor region. We can
estimate these two parameters for each voxels using the following equations:
𝜆
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Where, 𝜇𝑎𝑥 (𝑟 ′ ) are absorption coefficients obtained at imaging voxel 𝑟 ′ for a particular
𝜆

wavelength (x=730,780,800,830 nm). 𝜀𝑦 𝑥 (y=Hb or HbO2) is wavelength dependent extinction coefficient. The total hemoglobin concentration and oxygen saturation can be estimated using the
following two equations:
𝑡𝑜𝑡𝑎𝑙𝐻𝑏(𝑟 ′ ) = 𝑑𝑒𝑜𝑥𝑦𝐻𝑏(𝑟 ′ ) + 𝑜𝑥𝑦𝐻𝑏(𝑟 ′ )
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𝑌% =

𝑜𝑥𝑦𝐻𝑏(𝑟 ′ )
𝑡𝑜𝑡𝑎𝑙𝐻𝑏(𝑟 ′ )

2.3 Compact and Robust US-guided DOT System Design
Our group is working on ultrasound guided frequency domain diffused optical tomography for
over two decades. Chen et al. reported the first generation of ultrasound guided DOT in 2001 [13].
This system used only two wavelengths as light sources. It has 12 sources and 8 detectors and
guided by a 2-D ultrasound system, developed in the lab. This system provides promising results
with phantom study thus motivated the lab to develop the next version of the US-DOT system.
In the second version of the US-DOT system [14], the lab made ultrasound system was replaced
by a commercial ultrasound system, which is readily available in the examination site. A combined
probe holder was designed to integrate the ultrasound guidance for optical imaging. This version
was reported in 2006 and it has the option for selecting one of the three available modulation
frequencies. This version used three different wavelengths for light delivery to improve the
estimation of oxygenated hemoglobin information. This system was used in a clinical study and
successfully employed for diagnosing benign and malignant breast tumors. A software developed
using LabView programming controlled this 2nd generation DOT system.
Ten years after the second generation DOT, a new version of the DOT system was developed to
improve the performance of the previous generation [11]. Since no obvious advantage was not
achieved with the option with multiple modulation frequencies, in this version, only one
modulation frequency (140 MHz) was used. To further improve the performance in oxygen
saturation estimation, this system was equipped with a source of four different wavelengths. C++
based custom made software was used to control the data acquisition; however, data processing
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option was not available in the custom software. A customized data acquisition board was also
designed in the lab to provide better flexibility during the experiment. This system was used to
collect almost 300 patient data from three different hospitals in Connecticut, USA. This data
provides an effective means to evaluate the DOT system performance for neoadjuvant
chemotherapy monitoring.

Figure 2. 1 Block diagram of the ultrasound-guided DOT system. The DOT system consists of source and detection
subsystems controlled by a laptop through a FPGA.

To make the US-DOT technology suitable in the clinical settings, a new version of the US-DOT
system was required to provide better user-friendliness and robust data acquisition ability. In 2018,
we reported this latest version of the US-DOT system, which was intended to design for clinician
[15]. In this prototype, four laser diodes of wavelengths 730, 785, 808 and 830 nm were
sequentially switched by 4 x 1 and 1 x 9 optical switches to 9 source positions on a hand-held
probe. Fourteen photomultiplier tubes (PMT) receive the reflected light from each source location
simultaneously. After signal conditioning, the data is saved on the hard disk through the
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customized data acquisition board. The entire data acquisition requires about 3 to 4 seconds. The
sources and detectors were placed between 3.52 and 8.5 cm in the distance on the probe thus
provides us a reliable signal up to 5 cm depth. The system used heterodyne detection with the
laser diodes modulated at 140.02 MHz, and the detected signals were mixed with the 140 MHz
reference signal to separate the 20 kHz signal for optical image reconstruction. The output of the
mixer at each channel was further amplified and filtered at 20 KHz before passing to analog to
digital converter (ADC). An instrument case satisfying the medical safety standards was customdesigned and manufactured by Nexus LLC. Figure 2.1 shows the diagram of the system and Figure
2.2 shows the clinical set-up at the Radiology Breast Imaging Clinics of Washington University
School of Medicine in St Louis.

Figure 2. 2 Photograph of the US-guided DOT system used with a commercial US system. The system is used at
the Radiology Department of Breast Imaging Clinics of Washington University School of Medicine in St Louis.
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2.3.1 Electronic Component Design
Combined Mixer, Amplifier, and Filter
A custom-made detection circuit has been designed and built to miniaturize the detection
subsystem of the fourth generation DOT system. As this system has high frequencies (140MHz
and 140.02 MHz), the design needs to be robust to minimize the coherence noise at 20 kHz. The
primary challenge of designing this combined board was to reduce the multi-frequency
interferences. A three-layered printed circuit board (PCB) has been designed to meet this
challenge. Inserting a ground layer between the top and bottom layer reduced the interference. All
traces of a layer (top or bottom) carrier signal with a single frequency to provide better interference
immunity. Grounded (GND) through holes has been placed on both sides of the signal carrying
traces to provide better signal confinement. All these improvements result in a combined frequency
mixer, second-stage amplifier, and the bandpass filter in one miniaturized board to reduce the size
of the detection channel. A gain-adjustable second stage amplifier has been designed to provide
flexibility in controlling the dynamic range of the detection system.

Figure 2. 3 Combined mixer, amplifier and filter was used in each detector channel
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This combined board replaced three separate components (mixer, amplifier, and filter) of the
detection channel of the 3rd generation DOT system. While the three components in the previous
system occupied 22.5 cm X 3.0 cm X 5.5 cm in total, this combined board occupies only 10 cm X
3 cm X 5.5 cm. Therefore, 2887.5 cm3 volume was reduced using this new combined board design
for 14 detection channels. The lab designed filter also reduced the cost by $200 per channel. This
new combined board design not only reduces the cost and size, but it also provides comparable
noise performance. Noise performance has been measured after inserting this combined box for
several days with different combinations of the system state. Overall, recorded single-channel
noise was 7±8 mV, which is the same as the 3rd generation DOT system.

Figure 2. 4 Laser diode current driver for DOT source

Laser Diode Current Driver
The DOT system has two main blocks, source and detection subsystems. In our earlier prototypes,
we used four units of Thorlab’s DC current driver boards and four units of temperature-controlled
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laser diode mounts with an AC modulation port to drive four laser diodes. These units were bulky
and expensive. A custom-made laser diode driver board was designed to reduce the volume and
cost of these components. This board can accommodate up to six laser diodes of type A or C with
stable feedback control of DC current for each laser diode. Six built-in bias-tees, each with a radio
frequency (RF) input provides AC modulation to each laser diode output. The outputs of the laser
diodes were multiplexed via two optical switches (piezosystem jena) to 9 different positions on
the hand-held probe. Four miniature pigtailed laser diodes with a thermal block from OZ Optics
(LDPC-T3) were used as sources, and the temperature of the diodes was controlled using four
units of control modules from Thorlabs (TCM1000T TEC).

PMT Gain Controller
In this prototype, we have used PMTs for detecting reemitted signals for their superior sensitivity
and noise performance. Each PMT requires different gains to provide the same signal amplification
in all receiving channels. In the older versions, a potentiometer was used for each PMT to provide
different voltage to obtain the same signal output at each channel. This method makes data
acquisition slow and reduces the user-friendliness of the system. This limitation was eliminated by
designing a PMT gain controller board. This gain controller was designed using a 16-channel
digital to analog converter (DAC), which accepts a digital signal from the control software through
the custom designed data acquisition board, converted that signal into an analog voltage, and
provides desired gains to each PMT.

2.3.2 Light Delivery and Probe Design
The ultrasound probe was located in the center of the probe to localize the lesion. In order to use
PMT detectors in their maximum dynamic range and prevent the saturation when the source and
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detection positions are very close, the source-detector distances have been optimized by locating
nine sources on one side of the probe and the 14 detectors on the opposite side of the probe. Figure
2.2 insert shows the close-up view of the hand-held probe. A US transducer can be easily inserted
into the combined probe holder before coregistered imaging and then unplugged after imaging.
This handheld probe was designed and manufactured by an external contractor named Nexus LLC.

Figure 2. 5 PMT gain controller provides different gains to each PMT through control software

2.3.3 Data Acquisition Board
Same as the 3rd generation DOT system, we have used a custom-made Field Programmable Gate
Array (FPGA) based DAQ board to reduce the DAQ size and improve its robustness. This
miniaturized DAQ can accommodate up to 16 detection channels with two 8-channel ADC chips.
In addition to data acquisition, this board is used for controlling the optical switches, laser diodes,
and PMT gains. A laptop PC is used to communicate with the FPGA via a USB port. This
customized data acquisition board was designed for the third generation DOT system by an
external contractor. For the fourth generation system, it’s FPGA firmware has been modified to
add the control of laser diode diver and PMT gain control.
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2.3.4 PC Based Control Software
Improvements in robustness and user-friendliness of the software for DOT are among the most
critical steps toward extensive use in clinics. A new graphical user interface was developed using
C++ with three modules. The first module is DAQ as discussed above. The second module
consists of an automated system calibration [16]. The third module is for imaging reconstruction
which incorporates our recently developed outlier removal and data selection method before
reconstruction to eliminate the need for time-consuming data preprocessing [17]. It also includes
a semi-automated method to select the region of interest (ROI) from co-registered ultrasound
images and then uses the ROI for DOT image reconstruction [18]. This PC based control software
was updated with the help of other lab members and reported in ref. [15].

Figure 2. 6 Custom made 16 channel data acquisition board
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2.3.5 System Evaluation
Several phantom studies have been performed to evaluate the performance of the newly developed
system. These phantom studies were performed with the help of other lab members and reported
in ref. [15]. After obtaining satisfactory performance, the system was moved to Washington
University, School of Medicine for neoadjuvant chemotherapy monitoring. In the next two
sections, system evaluation methods and results have been provided in details.

Phantom Study
Multiple phantom experiments have been designed to evaluate the performance of the system.
Phantoms were placed in the Intralipid solution with an absorption coefficient of 0.015-0.02 cm-1
and reduced scattering coefficient of 7-8 cm-1. In the first sets of experiments, the sensitivity of the
system to differentiating high contrast and low contrast phantoms has been tested. Two sets of
solid phantoms with an absorption coefficient of 0.11 and 0.23 cm-1 and reduced scattering
coefficient the same as the Intralipid medium measured at 780 nm have been used. These
phantoms of three different sizes (diameters of 1, 2, 3 cm) located at different depths include two
small (1 cm) high and low contrast balls (SHC, SLC), two medium (2 cm) high and low contrast
balls (MHC, MLC), and two large (3 cm) high and low contrast balls (LHC, LLC).
Figure 2.7 shows an example of reconstructed images of an SHC ball located at the 1.5 cm depth
inside the Intralipid solution. The reconstructed maximum absorption coefficients of four
wavelengths (730, 785, 808 and 830 nm) are 0.233, 0.238, 0.216, 0.211 respectively.
Figure 2.8 shows the reconstruction accuracy (in %) of the maximum reconstructed absorption
coefficient of six solid high-contrast and low-contrast phantoms located at different depths. The
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absorption coefficient at the top depths of the phantoms are shown in the Figure. For high contrast
phantoms, our DOT system is accurate (89.4%) in the depth range of 1 to 2 cm for 1 cm diameter
phantom (89.4%, SHC), and 1 to 2.5 cm for 2 cm (97.2%) and 3 cm (87.6%) diameter phantoms
(MHC, LHC) . For low contrast phantoms, DOT system is accurate in the depth range of 0.5 cm
to 2 cm for 1 cm diameter phantom (73%), (SLC), and 0.5 to 2.5 cm for 2 cm (69.5%) and 3 cm
(72.1%) diameter phantoms (MLC, LLC). For high contrast phantoms located too close to the
surface for less than 1 cm, the accuracy of reconstruction is lower (64.4%) due to lacking central
sources in the combined probe.

Figure 2. 7 Reconstruction accuracy (%) for six different phantoms located at different depths (depth of the top
phantom positions are marked in the figure).
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Figure 2. 8 Target absorption maps (730nm, 785nm, 808nm, 830nm) of a SHC phantom located at 1.5 cm depth. For each absorption map, 7 slices from 0.5 cm
to 3.5 cm depth with 0.5 cm increment have reconstructed. The spatial dimensions of each slice are 9 cm by 9 cm. Color bar is the absorption coefficient in the
unit of cm-1.
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To further evaluate the stability of the system over time, a series of experiments of multiple
phantoms were measured at different days. One example of the stability result is presented in
Figure 2.9. It shows the maximum reconstructed absorption coefficients of the 1 cm diameter
high-contrast target measured at four optical wavelengths over time. The target was located at 1.0
cm in depth (target surface).

The experiments have been repeated for five days and one

measurement per day was performed. The average error for four wavelengths over five days was
5.4%, which is negligible considering the measurement errors of locating the targets precisely
inside the Intralipid solution at the desired depths.

Figure 2. 9 Maximum reconstructed absorption coefficient of the small high-contrast phantom located at 1.0 cm depth
(phantom top position) and imaged on different dates. The reconstructed absorption coefficients at 730,785, 808 and
830 nm are presented. The black dashed line represents the calibrated (true) absorption of the phantom.

Next, to evaluate the sensitivity of the system to oxygenated and deoxygenated hemoglobin, a
hollow glass bulb filled with oxygenated and deoxygenated hemoglobin was used as a blood
phantom. Hemoglobin solution was purchased from Instrumentation Laboratory (Multi-4, Level
2, Instrumentation Laboratory, MA) as the oxy-Hb sample. The Multi-4, Level 2 product
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specification provided by Instrumentation Laboratory is total hemoglobin 139 g/L, with HbO2
percentage of approximately 97%. The de-oxygenated hemoglobin (Hb) solution is prepared by
adding Sodium dithionite (Na2S2O4) solution into the diluted oxygenated hemoglobin (HbO2).
0.05 g Sodium dithionite is dissolved in 0.5 mL, phosphate buffer saline (PBS) solution (with 10
µL mixed solution corresponding to 1 mg Sodium dithionite) with a pH of 7.4. We then add the
Sodium dithionite solution into 3.5 mL HbO2 solution to prepare an Hb solution. Solution
preparation and mixing were carried out on top of dry ice to keep the temperature at around 0 °C
and slow down the speed of de-oxygenated Hb reacting with O2. After sealing the glass ball, we
incubated it at around 37 °C for 6 minutes for the Sodium dithionite to be effective. We calibrated
the de-oxygenating process with a standard UV-Vis spectrometer (Varian Cary®, Agilent, US).
For each ball and Hb solution, we finished our DOT measurements in less than 10 minutes. Figure
2.10 presents the experimental setup for the hemoglobin phantom experiments.

Figure 2. 10 (a) Glass ball (0.9 cm radius) filled with HbO2 solution and connected to holding fibers. (b) Sketch of
the experimental setup
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The images were reconstructed from measured data and the maximum reconstructed µ a were
compared with the calibrated values with the spectrometer. We used the maximum reconstructed
µa to compute SO2. We analyzed the DOT-measured SO2 of the hemoglobin target at different
calibrated SO2 values (~5-10% and ~97%) and Figure 2.11 shows the calculated spectrum from
our US-guided DOT system which follows the literature data [18]. The results of the DOT system
with four wavelengths are comparable with the data obtained from the spectrometer.

Figure 2. 11 Oxygenated and deoxygenated hemoglobin spectrum; reconstructed absorption coefficients using the
DOT system.

To evaluate the performance of the system sensitivity to oxygenated and deoxygenated
hemoglobin over time, five samples of oxygenated hemoglobin and five samples of deoxygenated
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hemoglobin were prepared separately on different dates and each sample was measured with the
spectrometer and then imaged with the ultrasound-guided DOT system.
Figure 2.12 shows the comparison of these five oxygenated and deoxygenated samples of
calibrated value with the spectrometer and calculated value with the DOT system. It can be seen
that the DOT measurements follow the spectrometer results closely.
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Figure 2. 12 Oxygenated and deoxygenated hemoglobin calibrated with the spectrometer and measured with the
DOT system.

Clinical Results
The system is currently being used in patients undergoing neoadjuvant treatment at Washington
University in St Louis. The study protocol was approved by the institutional review board and was
HIPPA compliant. Written informed consent was obtained from patients. The final pathologic
response was evaluated by the Miller-Payne system. In the Miller-Payne (MP) system, the patient
pathologic response is divided into five grades based on a comparison of tumor cellularity between
pre-neoadjuvant core biopsy and definitive surgical specimen. MP 1 and 2 are considered non-
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responders, MP 3 judged to be partial responders, MP 4 regarded as the almost complete
pathological response (pCR), and MP 5 deemed a complete pathological response (pCR).

Figure 2. 13 pCR of a triple receptor negative breast cancer of a 51-year-old woman with a high grade invasive ductal
carcinoma treated with carboplatin and docetaxel every three weeks for 6 cycles. Left panel: US images obtained at
pretreatment, at the end of cycle 1 (EOC1), 2 (EOC2), 3 (EOC3), and before surgery. On US, the tumor manifest as
an oval mass with well-defined margins, measuring 2.02 cm maximally before treatment, decreased mildly to 1.49 cm
at the completion of cycle 1, but was unchanged in size from the end of cycle 2 to before surgery. Right panel: tHb
concentration maps obtained at the corresponding time points. Each map shows six sub-images marked as slice 1 to
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6 and each sub-image shows spatial x and y distribution (9 cm by 9 cm) of tHb concentration reconstructed from 0.5
cm to 3.0 cm depth range from the skin surface. The spacing between the sub-images in depth is 0.5 cm. The color
bar is tHb in micromoles per liter. The tHb reduced from 83.3 mol/L measured before treatment to 69.0, 55.3, 37.9
mol/L measured before completion of cycle 1, cycle 2, and cycle 3. A reduction of 17.2%, 33.6%, 54.5% occurred at
the end of cycle 1, 2 and 3, respectively. The hemoglobin level remains unchanged to the end of the treatment before
surgery. This patient had a complete pathologic response with no residual tumor, Miller-Payne grade 5.

An example of conventional US and US-guided DOT generated Hb maps acquired throughout
neoadjuvant treatment in a 51-year-old woman with a pCR is shown in Figure 2.13. The patient
presented with a high grade (Nottingham Histologic Score 9/9) triple-receptor-negative, (i.e., ER,PR-,Her2Neu-) invasive ductal carcinoma and was treated with carboplatin and docetaxel every
three weeks for six cycles. US and US-guided NIR DOT was obtained prior to treatment, at the
completion of cycles 1, 2, 3 and before surgery. US image showed a substantial decrease from
baseline to the end of cycle 1, with more subtle size reduction during the remainder of neoadjuvant
treatment. US-guided NIR DOT shows a progressive decline in total hemoglobin (tHb)
concentration during the first three cycles, which correlated with a complete pathologic response
of MP grade of 5.

2.4 Algorithm Improvement for US-guided Diffuse Optical
Tomography
In the US-guided DOT approach, co-registered US images are captured and measurements of size
and depth are then incorporated in DOT reconstruction as a Region of Interest (ROI). A dual-zone
mesh image reconstruction is used to segment the ROI and background region with finer and
coarse mesh sizes. This scheme effectively reduces the total number of voxels with unknown
optical absorption for imaging reconstruction. Additionally, total absorption of each voxel is
reconstructed and the total is then divided by the voxel size to provide absorption distributions.
Because lesion absorption is higher than background in general, the total absorption, which is the
product of voxel size and lesion absorption, of a lesion in a smaller voxel is about the same scale
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of total absorption of background in a larger voxel. Therefore, the inversion is well-conditioned
and converges in fewer iterations. Thus, US identified ROI is critical to guide dual-zone mesh
DOT reconstruction.
Extraction of tumor size and location from US images has been done manually, which requires
experienced users to make these measurements and slows down the DOT reconstruction. Similar
to other medical imaging techniques, automatic US image segmentation is a challenging task,
because US image contrast is low and boundaries are often not clear due to speckle. Researchers
have explored several methods to obtain a reliable segmentation from medical images, which
includes operator assisted region growing techniques [19], rule-based segmentation where some
known image primitives are used for an unsupervised segmentation [20], atlas-based image
segmentation where a known structure is searched in the image for segmentation [21], and neural
network and c-mean clustering which generate statistical models to classify pixels into different
segments. In this manuscript, we introduce a simple adaptive threshold based method [22], which
is fast on data processing and easy for implementation; moreover, it also provides comparable
accuracy for DOT reconstruction as compared with manual processing. This method utilizes
image histogram to obtain an adaptive threshold for each input image. For some US images, the
posterior shadow of a tumor extends to the chest wall and make the segmentation difficult. To
avoid this problem, Hough Transform based line detection is used to determine the chest wall
location and use it as the deep boundary of the tumor.
20 patients (10 benign and 10 malignant cases) are used to evaluate the performance of the
segmentation method. Reconstructed absorption images are compared with manual processing
method and similar results are obtained. To the best of our knowledge, this is the first report of an
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automated segmentation method of using a US image to guide DOT image reconstruction. The
method can be implemented into MIR or x-ray guided DOT imaging reconstruction.

2.4.1 Extract Tumor Size and Location
To automatically detected lesion size and location for DOT reconstruction, an adaptive threshold
based segmentation method is used. For some cases, the posterior shadow of the tumor is extended
to the chest wall in the US images. In those cases, it is difficult to determine the tumor size because
the deeper boundary of the tumor cannot be accurately determined. Under these circumstances,
locations of the chest wall are determined and used as estimates of the deeper boundary of the
tumor. To determine the chest wall, Hough Transform [23] is used together with an edge detection
method.

Depth Markers

X-axis

Z-axis

Undesired Text

(a)

(b)

Figure 2. 14 (a) A typical US image captured in co-registration mode (b) Cropped US image

Pre-processing
A typical co-registered US image acquired by an image capture card is given in Figure 2.14 (a).
For reference, the horizontal axis is marked as z-axis and the vertical axis is marked as the x-axis.
Measurement in the y-axis is considered the same as the x-axis, assumed that lesions are symmetric
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in x and y-axis. Since the pixel intensity is the critical information needed in the segmentation
algorithm, the US grayscale image is automatically cropped first from the captured image using
Hough Transform and Sobel [24] edge detection method. Figure 2.14(b) shows the cropped US
image.

Figure 2. 15 Depth markers detected on US image

Depth marker detection is the next step before applying segmentation procedure because the
markers vary with depth range, which depends on the user selection from the front panel of US
machine. To determine the depth markers, a binary image is generated using a fixed pixel intensity
of 150 out of 256 gray scale levels as the threshold. Since the depth markers are mainly white, this
pixel intensity will help to separate them from the background. Then all the white regions consist
of 3 to 50 pixels and located outside of the right border of the US image are marked as depth
markers. This pixel range is obtained by examining the available US images collected from
different manufacturers. This depth marker detection procedure detects horizontal ticks along with
numbers which makes it suitable to use for images collected from a wide range of US machines.
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Figure 2.15 shows the captured image with automatically detected depth markers. When positions
of those depth markers are known, the difference between two markers in x-axis provides the
number of pixels per centimeter, which are then used to convert the measured tumor size and depth
into centimeter.

Adaptive Threshold-based Segmentation
To extract the required information from the US image, the first step is to segment the lesion from
the rest of the image. Then the radius and center of the lesion can be measured from the segmented
lesion. A single threshold point is used to separate the two zones, i.e., lesion and background. This
threshold point is determined adaptively for each input images. Because US images have speckle
noise, some complex segmentation techniques, such as fuzzy c-mean clustering, active contour
model [25] do not provide any improvement while demanding computation resources due to
complex processing. Moreover, DOT does not require precise segmented information. Thus,
instead of using a complex segmentation algorithm, threshold-based segmentation is used here to
obtain tumor information.
Lesions in breast US images usually appear as hypoechoic masses, which separate them from the
background tissue. To segment a hypoechoic mass, a threshold point is set to separate the tumor
from the rest of the image. US images usually have very low contrast. Histogram equalization is
applied on the grey scale image. Histogram equalization stretches the input histogram over the
available range which is 0 to 255 in greyscale and thus increases the contrast. Then a simple
procedure is followed to detect the threshold point adaptively. Since the intensity varies
significantly between different images, it is the best to use an adaptive threshold point for every
input images.
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This adaptive threshold point detection procedure starts with obtaining the histogram of the US
image. Figure 2.16 (a) shows the histogram of an input image. The histogram shows a peak and a
hump with a notch between them as indicated in the figure. This histogram shape is obtained from
all US images after histogram equalization because of the presence of a significant amount of black
(provides the peak) and grey pixels (the hump) in a US image. This notch shows the threshold for
separating the grey background from the black tumor. To detect this point automatically, the slope
of the histogram envelope is calculated. Pixel intensity of the point when the sign of the slope has
changed is considered as the threshold value. In the next step, this threshold value is used to
generate a binary image.

Inserted Seed

Threshold

(a)

(b)

Figure 2. 16 (a) Histogram of a US image; threshold is marked with an arrow (b) Inserted seed on the cropped image
by user

After obtaining the threshold for the US image, a binary image is generated where the tumor region
is marked as black and background are white. However, the tumor is not the only black zone in
the binary image. To remove the unwanted black regions user needs to insert a seed in the
approximate tumor location by clicking the tumor in US image as shown in Figure 2.16 (b). If
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there exist multiple tumors, then multiple seeds are required to be inserted in the probable
locations. Any region that is not containing the seed is discarded. Finally, only the tumor region is
survived. Then the MATLAB function ‘regionprop' is used to measure the tumor center and radius
automatically. This information is then passed to the optical reconstruction code. The flow diagram
in fig. 2.17 shows the steps for the entire procedure.

Input Image

Enhance
contrast

Adaptive
threshold

Tumor
boundary
Detection

Measure
tumor center
and radius

Figure 2. 17 Flow diagram of the tumor boundary detection procedures

2.4.2 Chest Wall Detection Using Hough Transform
Detection of chest wall depth is not essential to obtain tumor location and size. However, for some
cases when the posterior shadow extends to the bottom of the US image, it is difficult to define the
bottom of the tumor. In such cases, chest wall location is considered as the bottom of the tumor.
We defined chest wall depth as the distance from the skin to the top layer of chest wall muscle. An
automated chest wall depth detection method was developed and applied to the co-registered US
images. Detection of the chest wall is based on the fact that chest wall muscles appear as line
structures in US images (see Figure 2.18 (a)) [26]. Therefore, line detection algorithms can be used
for automatic detection. We chose Hough Transform as a line detection method because it is robust
and straightforward when combined with an edge detection method. Here, Canny edge detection
[27] is used as an edge detection method. The binary image generated by the Canny edge detection
is shown in Figure 2.18 (b).
It is clear from Figure 2.18 (b) that if Hough transform is applied to the edge detected image
without any restriction, it will detect several unnecessary structures. For example, due to
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subcutaneous fat and breast tissue interfaces, some linear structures appear at the top of the US
image. There are other linear structures also visible in the image. Hough transform detects all these
linear structures. To avoid these unnecessary line structures, we modeled chest as a linear structure
which is mainly horizontal with a small slope and it should appear at the lower half of the image.
After applying Hough transform and restrictions mentioned above, survived linear structures are
marked in green lines as shown in Figure 2.18 (c). Finally, the mean value of all the points of these
detected lines is considered as the chest wall depth. A flow diagram of the entire procedure is given
in Figure 2.19.

Chest wall
(a)

(b)

(c)

Figure 2. 18 (a) Breast US image with chest wall marked with arrows. (b) Edge detected binary image from (a).
(c) Detected chest wall location on the original input image. The yellow and red stars indicate the separation points
between line pieces. Green lines indicate the detected linear structures after restriction applying.

Input image

Canny edge
detection

Line detection
using Hough
Transform

Tested with
defined
model

Chest wall
depth

Figure 2. 19 Flow diagram of the chest wall detection method

2.4.3 Results
The proposed US segmentation method is evaluated in two steps. First, the US segmented
reconstruction results are obtained and deviation is calculated against manually segmented
reconstruction results. Second, both automated and manually segmented results are used to
generate absorption maps and the corresponding hemoglobin concentration maps and compared.
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Validation of US Segmentation
To evaluate the performance of the US segmentation algorithm, tumor boundary for all 20 cases
were delineated by an experienced US image examiner. These readings are taken as standard in
this study. Then the experimental results were compared with those manual measurements.
Two input images with manually marked tumor boundaries are presented in Figure 2.20 (a) and
2.23(a). In Figure 2.20 (b) and 2.23(b), segmented images using the proposed method are
presented. It is clear from these figures that the segmented tumor by the proposed algorithm is
comparable to the manual measurement. To obtain a quantitative evaluation of the US
segmentation procedure, US images from 10 benign and 10 malignant cases are collected. The
center coordinate of the tumor and radius in both axes are measured manually. The same
information is also collected from the proposed segmentation method. The deviation is calculated
between the two methods for 20 images. Comparison of the average measurements from these 20
images is given in Table 2.1. From the table, we found that manual measurements are slightly
smaller than the proposed measurement. However, deviation from different measurements never
exceeds 0.25 cm, which is the resolution of the optical reconstruction. So, optical reconstruction
will not be affected by this small deviation.
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Figure 2. 20 (a) US image with manual markers to measure sizes of the tumor. The measurements were 3.1cm in
spatial direction x and 1.6 cm in depth direction z using manual measurements. (b) Segmented US image using the
semi-automated procedure and the measurements were 3.3 cm in spatial x direction and 1.6 cm in depth direction.
Table 2. 1 Comparison between manually and semi-automatic extracted information from US images

Manual
Segmentation

Proposed
Segmentation

(cm)

(cm)

Deviation
=Manual-proposed
(cm)

z center position

1.49

1.56

-0.07

Benign

x center position

0.14

0.19

-0.02

Cases

z-radius

0.95

0.97

-0.1

x-radius

1.55

1.65

-0.05

z center position

1.9

1.98

-0.07

x center position

0.13

0.15

-0.03

z-radius

1.15

0.99

-0.06

x-radius

1.34

1.4

-0.03

Malignant
Cases
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To evaluate the repeatability of the proposed US segmentation algorithm, we have measured four
parameters (lesion depth, z-radius, x-radius, x-center) from three different sets of US images and
reconstructed the corresponding total hemoglobin maps. For each case, these images were
collected from the same lesion location; however, some deviation was expected because the
operator intended to hold the probe still for each data set and may move little between different
data sets to obtain best US images. For each case, mean and standard deviation are given in Table
2.2. This deviation for depth is less than 1.5 mm and for other three spatial measurements is
smaller than 0.25 cm (image grid size) and thus does not have any significant effect on optical
reconstruction. As shown from the table, the maximum deviation obtained from benign cases is
4.45 µM and 2.06 µM for the malignant case.

Figure 2. 21 (a) US image with manual markers to measure sizes of the tumor. The measurements were 0.88 cm in
spatial direction x and 0.77 cm in depth direction z using manual measurements. (b) Segmented US image using the
semi-automated procedure and the measurements were 0.9 cm in spatial x direction and 0.73 cm in depth direction.

Validation of Optical Reconstruction
The ultimate goal of the US segmentation algorithm is to assist DOT reconstruction. In this section,
the performance of optical reconstruction is evaluated using tumor information extracted from both
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Table 2. 2 Evaluation of the repeatability of the proposed method

Depth (cm)

z-radius
(cm)

x-radius
(cm)

x center
(cm)

Total Hemoglobin
(µM)

1.86 ± 0.042

1.48 ± 0.074

2.02 ± 0.233

0.47 ± 0.048

23.66 ± 0.905

1.78 ± 0.001

1.57 ± 0.006

3.45 ± 0.189

0.3 ± 0.014

62.81 ± 0.384

1.69 ± 0.013

1.44 ± 0.079

3.07 ± 0.118

0.45 ± 0.124

50.25 ± 4.452

2 ± 0.006

0.4 ± 0.006

0.53 ± 0.006

0.58 ± 0.143

62.69 ± 0.362

1.08 ± 0.003

0.39 ± 0.019

1.03 ± 0.070

-0 ± 0.026

42.33 ± 0.001

Benign

1.18 ± 0.006

0.56 ± 0.009

1.12 ± 0.166

0.09 ± 0.051

28.26 ± 0.022

Cases

1.61 ± 0.036

0.75 ± 0.024

1.61 ± 0.046

-0.1 ± 0.297

67.15 ± 0.018

1.16 ± 0.009

0.24 ± 0.009

0.49 ± 0.024

0.15 ± 0.116

123.58 ± 0.317

1.8 ± 0.040

2.52 ± 0.083

3.46 ± 0.114

-0.01 ± 0.079

64.11 ± 0.002

1.32 ± 0.020

0.26 ± 0.004

0.48 ± 0.042

0 ± 0.013

83.98 ± 0.002

1.35 ±0.019

0.72 ± 0.012

0.93 ± 0.027

0.21 ± 0.117

109.78 ± 0.129

2.55 ± 0.031

1.92 ± 0.029

2.84 ± 0.065

0.16 ± 0.077

172.66 ± 0.000

2.97 ± 0.018

1.45 ± 0.036

2.34 ± 0.016

-0.63 ± 0.243

198.14 ± 1.734

1.66 ± 0.008

0.88 ± 0.009

1.07 ± 0.031

0.48 ± 0.106

93.36 ± 2.061

Malignant

2.03 ± 0.029

0.65 ± 0.078

0.43 ± 0.009

-0.49 ± 0.035

95.73 ± 0.038

Cases

1.45 ± 0.027

1.09 ± 0.009

1.45 ± 0.024

0.52 ± 0.079

107.23 ± 1.375

2.59 ± 0.001

0.3 ± 0.030

0.55 ± 0.014

0.19 ± 0.028

135.49 ± 0.060

1.94 ± 0.073

1.34 ± 0.137

2.76 ± 0.219

0.53 ± 0.082

77.77 ± 0.556

1.79 ± 0.014

0.77 ± 0.026

0.81 ± 0.037

0.46 ± 0.099

156.49 ± 0.992

1.57 ± 0.016

0.65 ± 0.000

0.97 ± 0.015

0.24 ± 0.010

88.84 ± 0.001
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manual and proposed segmentation process. Optical data of the same 20 patients were used to
generate absorption maps for four different wavelengths. Then the absorption information is used
to obtain hemoglobin concentration. Both manual and semi-automatic features are used to generate
different absorption maps. In Figure 2.21 and 2.22, absorption maps for a benign case are
compared and a malignant case is presented in Figure 2.24 and 2.25. It is clear from these figures
that the reconstructed map is almost similar. Average maximum absorption from 20 cases is
compared in Table 2.3. From the table, we can see that mean optical absorption obtained from
manual measurement was 0.21±.06 cm-1 for malignant and 0.12±.06 cm-1 for benign cases, where
for the proposed method it was 0.24±.08 cm-1 for malignant and 0.12±.055 cm-1 for benign tumors.
Finally, Figure 2.26 shows boxplots for oxygenated, de-oxygenated and total hemoglobin
concentrations for the same 20 cases for both manual and proposed automated procedure. We can
see from this figure that results for both techniques are almost similar. For benign cases, mean
total hemoglobin concentration for all 10 cases is 58.95±27.76 µM from manual segmentation and
58.64±27.93 µM for the proposed automated segmentation. For malignant cases, this measurement
is 115.23±39.62 µM from manual segmentation and 114.64±49.66 µM for the automated
segmentation. Values for oxygenated hemoglobin, for benign cases, is 35.73±20.67 µM for manual
segmentation method and 38.32±21.67 µM for proposed segmentation method. For malignant
cases, this measurement is 72.30±23.07 µM and 75.27±27.92 µM for manual and proposed
segmentation method respectively. Deoxygenated hemoglobin concentration is 35.41±15.31 µM
and 37.13±16.21 µM for benign cases using manual and proposed segmentation method
respectively. For malignant cases, this measurement increases to 50.26±19.63 µM and
48.04±22.88 µM for manual and proposed segmentation method. Thus, the performance of the
proposed feature extraction technique is quite acceptable.
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Figure 2. 22 Optical absorption maps of four wavelengths using three times of the size measured by US in x-dimension. Depth used in optical reconstruction is
the same as US measurement. Each optical absorption map has seven image slides of 0.5 cm from the skin surface to the chest wall with 0.5 cm step in depth.
Manually measured tumor information from 2.20 (a) is used in these maps
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Figure 2. 23 Optical absorption maps using three times of the size identified by US in x-dimension. Depth used in optical reconstruction is the same as US
measurement. Tumor information for these maps was extracted from 2.20 (b)
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Figure 2. 24 Optical absorption maps of four wavelengths using three times of US measured size in x and same size as US measurement in z. Tumor dimension
and location was extracted from 2.23 (a) to generate these maps
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Figure 2. 25 Optical absorption maps using three times of US measured size in x and same size as US measurement in z. To generate these maps tumor
information was extracted from 2.23 (b).
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Table 2. 3 Average absorption coefficient using manual and automatically segmented tumor information

Average (Standard Deviation) of maximum reconstructed absorption
with manual tumor segmentation(cm-1)
Malignant

Benign

Ratio

740 nm

0.19 (0.08)

0.11 (0.06)

1.72

780 nm

0.22 (0.07)

0.12 (0.06)

1.83

808 nm

0.22 (0.05)

0.14 (0.08)

1.57

830 nm

0.22 (0.05)

0.13 (0.05)

1.69

Average (Standard Deviation) of maximum reconstructed absorption
with proposed tumor segmentation(cm-1)
Malignant

Benign

Ratio

740 nm

0.21 (0.08)

0.14 (0.05)

1.5

780 nm

0.25 (0.09)

0.12 (0.05)

2.08

808 nm

0.24 (0.08)

0.12 (0.06)

2

830 nm

0.24 (0.08)

0.12 (0.06)

2

Figure 2. 26 Comparison of total hemoglobin concentration for 10 benign and 10 malignant cases.
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2.5 Summary
System and algorithm development for diffuse optical tomography was one of two aims of this
PhD research. To make the ultrasound-guided diffuse optical tomography technology suitable for
clinical applications several design modifications have been done. Probe holder for the system was
redesigned to accommodate the optimized source and detector locations. Instead of purchasing the
commercial laser current drivers and heat sink, custom designed current driver was used which
reduced the cost and area requirements as well as added flexibility in component placement and
spacing. In the detector side, combined mixer, amplifier and filter board design make the detector
more compact than the previous prototype, significantly reduced the cost and provided a similar
performance in terms of signal integrity. Software controlled PMT gain setting was an important
step to make the system more suitable for clinical technicians. After all these system modifications,
users now can control the system using the graphical interface of the software and thus satisfied
the critical goal of this research which is making the ultrasound-guided diffused optical system
suitable for clinical application.
Semi-automatic segmentation of tumor in the ultrasound image was another component that makes
the optical image reconstruction less operator dependent. This segmentation procedure requires
minimum input from the users, which make this image reconstruction procedure suitable for
anyone with little knowledge about breast ultrasound images. A part of this segmentation
algorithm was automatic chest wall detection, which proved suitable for another study where the
chest wall height of several hundreds of breast ultrasound images was determined using this chest
wall detection algorithm. Current DOT image reconstruction is providing meaningful optical
reconstructed images from over 90% cases. Improvement is going on to make it more effective.
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3 Ultrasound Guided Photoacoustic
Tomography
Alexander Graham Bell first reported photoacoustic effect in the late 1800s [1]. However,
photoacoustic imaging was not feasible for clinical diagnosis until the advances made in ultrasound
transducers, computers, and laser systems. Wang et al. [2] reported some early experiments
demonstrating the efficacy of photoacoustic tomography for medical imaging. In photoacoustic
tomography, acoustic waves are generated by shining the tissue with short duration NIR laser
pulses. The amplitude of the acoustic wave depends on the number of photons absorbed by the
tissue. Conventional ultrasound transducers can be used to detect this acoustic wave, which makes
this technology suitable to use in clinical settings. Since human tissue is highly scattering medium
for photons, photons cannot reach deeper than 5 cm inside an organ; thus, PAT has depth limitation
of 5 cm, which is suitable for many applications including ovarian cancer detection.
Ovarian cancer is the deadliest among all gynecological cancers. It has five years survival rate of
less than 30% when detecting at stage III or IV. However, survival change can dramatically
increase to 80-90% when it is discovered in stage I or II [3]. Unfortunately, most of the time this
cancer can develop inside the human body without expressing any significant symptoms. Thus,
make it very hard to detect at an early stage. Lack of suitable tools to early diagnose of ovarian
cancer makes the diagnosis even harder. Therefore, any patient with ovarian abnormality has to go
through oophorectomy, which significantly reduces the quality of life of the patient. Currently
used methods, i.e., CA125 screening, CT, ultrasound, MRI still struggling to improve the
sensitivity and specificity [4]–[9]. Our newly developed PAT system has demonstrated huge
potential for early detection of ovarian cancer in a convenient way.
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This chapter will present the image reconstruction principles of US and PAT followed by their
application is an ovarian cancer diagnosis. It consists of the description of our newly developed
system, evaluation report, and solution for a practical problem.

3.1 Imaging Principle
For ovarian cancer diagnosis, we are using co-registered ultrasound and PAT images and RF data.
Following two sections will briefly describe the relationship between the Co-registered US/PAT
images and ovarian cancer diagnosis.

3.1.1 Ultrasound Imaging
Compressional waves are used in ultrasound imaging to image tissue mechanical properties.
Particles inside the medium compress and extend to propagate the wave through the medium.
Ultrasound transducers are generating a propagating wave by vibrating at the tissue surface. This
vibration creates a local pressure p, which propagates along the z-axis. Thus, the pressure wave
equation can be expressed by:
𝜕 2𝑝
1 𝜕 2𝑝
−
=0
𝜕 2 𝑧 2 𝑣𝑠2 𝜕𝑡 2

3. 1

Where 𝑣𝑠 is the speed of sound in medium (about 1500 m/s in human tissue). This equation will
take the following form when expressing the equation for the 3D space.

∇2 𝑝 − 𝜌𝐾

𝜕 2𝑝
=0
𝜕𝑡 2

3. 2

Where 𝜌 is the density of the medium and K is the compressibility constant which is related to the
pressure-velocity using the following equation,
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3. 3

1
𝑣𝑠 = √
𝜌𝐾

When ultrasound wave propagates through the medium, its velocity is affected by the acoustic
impedance of the medium which can be expressed by the following equation,

𝑍=

𝑝
𝜌
= 𝜌𝑣𝑠 = √
𝑣
𝐾

3. 4

When the propagating US wave enters from one type of tissue to another type of tissue with
different acoustic impedance, then some portion of the wave is reflected from the tissue boundary.
The reflection coefficient of the tissue determines the portion of the incident wave enters the
second medium, and the portion is reflected the first medium. The incident angle of the wave and
the acoustic impedance of the mediums determine the reflection coefficient of the tissue. When
the wave propagates from medium 1 to medium 2, the reflection coefficient can be expressed using
equation 3.5,

𝑅=

𝑍2
𝑍1
(𝑐𝑜𝑠𝜃
) − (𝑐𝑜𝑠𝜃
)
𝑡

3. 5

𝑖

𝑍2
𝑍1
(𝑐𝑜𝑠𝜃
) + (𝑐𝑜𝑠𝜃
)
𝑡
𝑖

Where 𝜃𝑡 and 𝜃𝑖 are the transmission angle and incident angle respectively, and Z1 and Z2 are the
acoustic impedance of medium 1 and medium 2 respectively. As shown in Figure 3.1, the incident
ultrasound wave is reflected from different tissue boundaries as they have different acoustic
impedances. This recorded signal is called A-line. Multiple A-lines are combined to reconstruct a
US image.
Other than the transmission and reflection, the acoustic wave is also affected by the attenuation of
the tissue. Thus, as the wave propagates deeper in the tissue its amplitude attenuates and soon goes
below the noise level. This attenuation is inversely proportional to the frequency of the incident
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wave. The attenuation for the softest human tissue is between 1.35 and 1.68 dBcm-1MHz-1. All
medical US image reconstruction procedure tries to estimate the pressure distribution inside the
human body from the reflected waveform, which is captured by the transducer. This pressure
distribution is related to the internal structure of the subject, which may reveal significant clinical
information. Since the ovarian tumor has a different structure than the background, using US
images, it can be readily separable from the background. Some extracted features from US beams
can be used for diagnosing benign and malignant tumors as they are related to the structure of the
subject [10].

Figure 3. 1: Ultrasound wave reflected from different tissue boundaries [11]
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Two types of US images can be generated using the US system. Stacking multiple A-lines at
different times will produce M-mode images, which reveals the pressure change with time. On the
contrary, stacking a-lines collected at different locations generates B-mode images. For ovarian
cancer detection, we are interested in B-mode imaging because ovarian tumor changes its shape
very slowly thus collecting meaningful information from M-mode images will take a long time,
which is not feasible in the clinical setting. In the rest of the chapters, B-mode US image will be
referred to as US image, since in our experiments we never work with M-mode images.
B-mode ultrasound images can be collected by shifting a single transducer in space to collect alines at various locations. However, this method is not fast enough to obtain good quality images.
In our applications, we have used an ultrasound transducer array, which consists of multiple
ultrasound transducers at close spacing. By applying electric pulses at a variable delay, a focused
steering wavefront can be generated. When the reflected signal came back, they can be added after
delay correction to obtain a focused beam. This method is shown in Figure 3.2 and 3.3.
Several features related to the mechanical properties of the tissue can be derived from US beams.
After the beamforming, demodulating the carrier signal provides an envelope signal. After scan
conversion, a B-mode US image is obtained from this envelope signal. These steps of US image
reconstruction is presented in Figure 3.4.
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Figure 3. 2 Transmission focusing and steering in US mode [11]

Figure 3. 3 Receiving Beamforming in US mode [11]

Digital signal
from US
transducer

Delay and
Sum
beamforming

Demodulator

Scanconversion

Figure 3. 4 High-level block diagram for US image reconstruction
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US image

3.1.2 Photoacoustic Imaging
Obtaining functional information from the target location is the primary motivation for
photoacoustic imaging. In PAT mode, short laser pulses are applied to the tissue to produce
acoustic waves, which is detected by ultrasound transducers. During PAT imaging, effect of
intense light scattering inside the human tissue is reduced by using the acoustic detection, at the
same time information related to the light absorption is preserved by using light to generate
acoustic waves. Thus, PAT combines the advantages of optical and US imaging.
When the short laser pulses shine the tissue surface, it creates acoustic pressure as expressed by
the following equation,

𝑝0 =

𝛽
𝜂 𝐴
𝜅𝜌𝐶𝑉 𝑡ℎ 𝑒

3. 6

Here, 𝛽 is the thermal coefficient of the volume expansion, 𝐶𝑉 denotes the specific heat capacity
at constant pressure, 𝐴𝑒 is the specific optical absorption and 𝜂𝑡ℎ is the heat conversion efficiency
of the target. Optical absorption is the product of the absorption coefficient of the target 𝜇𝑎 and
the incident fluence F. After replacing the optical absorption and the constants with Grueneisen
parameter, equation 3.6 can be expressed as,
𝑝0 = Γ𝜂𝑡ℎ 𝜇𝑎 𝐹

3. 7

This is the initial pressure that we want to image in PAT images. This pressure wave propagates
in 3D space following the forwarding wave equation, which is expressed in equation 3.8

(∇2 −

1
𝑣𝑠2 𝜕𝑡 2

)𝑝(𝑟⃗, 𝑡) = −
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Γ 𝜕𝐻(𝑟⃗, 𝑡)
𝑣𝑠2 𝜕𝑡

3. 8

𝐻(𝑟⃗, 𝑡) = 𝜂𝑡ℎ 𝜇𝑎 𝐹(𝑟⃗, 𝑡)

3. 9

As we can see from equation 3.8, pressure propagation of the PAT wave follows the propagating
wave equation. Thus, solving this equation can provide us the PAT distribution in 3D space.
Unfortunately, pressure distribution reconstruction by solving this equation requires 3-D
ultrasound transducer, which can record spherical wave, propagates from the pressure source. This
type of transducer is very expensive and not suitable for clinical application. Thus, we are using
an ultrasound transducer array to capture a portion of the propagating wave. Then apply the similar
delay and sum algorithm describes in section 3.1.1 to reconstruct a PAT image. This is certainly
not providing the exact initial pressure estimation but provides enough information to diagnose
benign and malignant ovarian cancer by providing light absorption related to tissue
microvasculature.

3.2 Photoacoustic System Development
PAT has already demonstrated its efficacy in deep tissue imaging [12]. To utilize the advantage of
PAT imaging, several systems [13]–[19] has been developed. However, none of them provided
real-time US/PAT images. Our group has developed several US/PAT systems for co-registered
US/PAT imaging [17][14][20][21]. Alqasemi et al. have developed a 128 channel real-time
US/PAT system which can provide co-registered US/PAT images at 15 frames per second [21].
This system has been used for both ex-vivo [22] and in-vivo [23] sample study. However, the
image quality of the system was degraded over time due to poor connections and grounding.
In this research, we focus on developing a coregistered US/PAT system for in-vivo ovarian cancer
characterization. This system utilizes the PAT modality to provide functional parameters of
ovarian tumor and structural information can be obtained from US images. Along with the real-
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time coregistered US/PAT images, this system can save raw data, which could be utilized to extract
other spectral features during offline processing. This system was customized from a commercial
US system for real-time coregistered US/PAT data acquisition and processing. A Ti:Sapphire
optically pumped Q-switched Nd:YAG laser has been used as a light source. A 3D printed probe
holds four optical fibers around the US transducer for shining the tissue sample. During the
experiment, data obtained using four wavelengths to calculate oxygen saturation. Wavelength
tuning and data saving have been synchronized using a C++ based customized control software
loaded on a separate control computer. Different system parameters have been evaluated using
phantoms before using it for human subject imaging.

3.2.1 Customizing Commercial Ultrasound System
A commercial US system (EC-12R, Alpinion Medical Systems, Republic of Korea) was
programmed to obtain PAT data for this study. This machine can read instructions written in
python; thus it is possible to operate it in US, PAT or co-registered US/PAT mode. This system
can save raw PAT data, which can be acquired for offline processing and feature extraction. This
US system receives ten ns trigger pulse at 15 Hz rate from the laser source and saves one PAT
frame data at each trigger pulse. One US frame data was also collected with each PAT frames
when operating in co-registered mode. More details regarding the system can be found in [17].

3.2.2 Automatic Wavelength Tuning
In this study, we have used four different wavelengths (740, 780, 800, 830 nm) to illuminate the
same spot sequentially and saved the corresponding US and PAT data. Customized software was
developed to sweep the wavelengths and collect data automatically. This software can be set to
sweep over some fixed wavelengths or a user-defined range of wavelengths with a set interval.
This control software was loaded on a laptop, which is connected to the US system using an
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Ethernet cable and the motor driver (for wavelength tuning) using a serial port. Along with the invivo patient data, we have collected ex-vivo sample data. This software can also control the stage
for ex-vivo data collection automatically. The whole control block is shown in Figure 3.5.

Figure 3. 5 Control block of real-time coregister US/PAT system

Figure 3. 6 3D printed handheld probe for holding optical fiber around ultrasound transducer

3.2.3 Probe Design
A 128-channel curved trans-vaginal US transducer was used for the study, which has a center
frequency of 6 MHz with 80% bandwidth. It has an elevation height of 6 mm and 145.5-degree
field of view. Four 1 mm core optical fibers were arranged around the transvaginal probe to deliver
light to the sample. A 3D-printed hand-held probe (Figure 3.6) was designed to hold these optical
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fibers around the US probe. Inside and outside of the 3D-printed probe was covered by thin
aluminum tape with 85% reflection coefficient at 750 nm for high-intensity light output. The
position of the optical fibers was determined to obtain optimum light energy at 10 mm away from
the probe, which is typical vaginal muscle thickness.

3.2.4 Optical Setup
Optical setup for this system was adapted from the optical setup used in the previous version of
real-time PAT system developed by our group [23]. Briefly, A Ti:Sapphire (Symphotics TII, LS2134, Symphotics, Camarillo, California) optically pumped with a Q-switched Nd:YAG laser
(Symphotics-TII, LS-2122) has been used to illuminate the sample orthogonal to the imaging plane
of the transducer. The laser can deliver 8 to 12 ns trigger pulses at 15 Hz with tunable wavelength
from 680 to 950 nm. A stepper motor (Sigma Koki SGSP-25ACTR-B0) was connected with a
crystal to tune the wavelength automatically. A motor driver (LOTIS TII CU 2350) controls this
motor, which can receive the command from external PC using a serial port.
Laser output from this system was passed to the four optical fibers through a custom-made lens
array that consists of four cylindrical lenses (12.5mm H x 25mm L x 150mm FL Cylinder Lens
VIS-NIR Coating, Edmund Optics PCX). This lens array split the incoming beam from the laser
into four beams. A 90-10 beam splitter withdraws a portion of the output laser before the incident
on the custom-made lens. This splitted laser beam is converted into electrical pulses using a single
element US transducer and saved in a computer using a data acquisition card (NI PCI-5112). The
saved fluence information is later used for signal normalization. The complete system with the
optical setup is shown in Figure 3.7.
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3.2.5 Results
System Calibration
Before collecting patient data, system performance was evaluated using phantom experiments. US
transparent, opaque blood-filled Silicon tube was inserted inside the chicken breast to mimic the
blood vessel inside the vagina muscle wall. Then the chicken breast was merged into 0.04%
intralipid solution.

Co-registered US/PAT data was collected at different depths for SNR

(20log10(max PAT envelope/system noise)) measurements at 780 nm. PAT signal strength was
measured from the blood tube location, and the noise was measured after removing the chicken
breast. SNR vs. depth plot is shown in Figure 3.8. From the figure, we can see that the SNR is
plummeting at 7.3 dB/cm. With this rate, we can obtain a reliable signal (3dB) up to ~3.5 cm.
Noise equivalent depth (0 dB) was ~4 cm.

Figure 3. 7 Experimental setup for the real-time co-registered PAT system
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The axial resolution of the co-registered US/PAT system is also measured using a 250 µm black
thread with 780 nm light. This black thread is placed perpendicular to the imaging plane at the 0degree position and worked as a point source. PAT signal coming from the black thread was
measured after putting it inside a water tank at four different depths from 0.5 to 2 cm with 0.5 cm
interval. Then FWHM was calculated from the fitted Gaussian curve after deconvolution with the
transfer function of the transducer. The measured axial resolution was 250.25±44.45 µm.

Figure 3. 8 Depth vs SNR

Clinical Results
From February 2017 to November 2017, 16 patients were enrolled for ovarian tumor imaging at
the Siteman Cancer Center of Washington University in St. Louis. These patients were at risk for
ovarian cancer or had an ovarian or pelvic mass suggestive of malignancy. The study protocol was
approved by the institutional review board (IRB) and compliant with the Health Insurance
Portability and Accountability Act (HIPAA). Written informed consent was obtained from all
patients. Before imaging with the PAT/US system, all the patients were imaged by a radiologist
(CS, or CR) assisted by a US technician using a commercial transvaginal US system of GE. After
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examining the suspicious ovaries or pelvic mass, the commercial probe was then withdrawn, and
the customized PAT/US probe was inserted transvaginally to image the suspicious masses. For
each imaging location, 5-10 PAT and US frames were recorded for all four wavelengths.
Of the 16 patients, one patient did not have any ovarian mass found from US imaging prior to
PAT/US imaging, and one patients’ data was not recorded properly due to system related
problems. For the rest 14 patients, one patient had one ovary detected by the commercial
ultrasound system; however, the location was too deep (> 5 cm) for PAT/US imaging. Of the total
13 (mean age 52 years, range 37 to 63 years) patients, one patient’s data was recorded only for a
single wavelength (780 nm) due to laser tuning problem and this patient’s data was used for
spectral analysis. For the rest of 12 patients, six patients had one ovary due to prior surgeries or
cannot find from the commercial US system. As a result, 18 ovaries from 12 patients were imaged
with co-registered PAT/US system and consisted of high grade serous carcinomas (n=2) and
endometrioid adenocarcinoma (n=3), serous borderline tumors (n=2), sex code stromal tumor
(n=1), benign fibrothecoma (n=2) and normal ovaries (n=2), benign cystic ovaries (n=6). The
patient information and diagnosis based on surgical pathology are provided in Table 3.1. Example
of an invasive cancer and a benign ovarian mass are presented in Figures 3.9.
Table 3. 1 Patient characteristics and surgical pathology of ovaries

Patient

Age
(y)

Menopaus
al status

Serum
CA125
(U/ml)

001

37

pre

85.4

(n=2)

Surgical pathology of the tubes and ovaries

Right ovary (4.5 cm): serous borderline tumor
Left ovary (9.5 cm): serous borderline tumor

65

002

55

pre

2442

(n=2)

Right ovary (11.5 cm): high-grade serous
carcinoma, involving the ovarian parenchyma and
surface
Left ovary (8.5 cm): high-grade serous carcinoma,
involving the ovarian parenchyma and surface

003

63

post

93

(n=2)

Right ovary (3 cm): endometrioid adenocarcinoma,
well-differentiated; steroid cell tumor
Left ovary: no histopathologic abnormality

004

61

post

16.3

Left ovary (13 cm): fibrothecoma

50

pre

116.3

Right ovary (8.3 cm): endometrioid
adenocarcinoma, well differentiated, involving
ovarian surface

(n=1)
005
(n=2)

Left ovary (20 cm): endometrioid adenocarcinoma,
well differentiated, not involving ovarian surface
006

57

post

19

(n=2)
007

Left ovary (3 cm): cystic follicles
42

post

11.4

Left ovary (19.2 cm): Sertoli-Leydig cell tumor,
intermediate/moderate differentiation, not present
on ovarian surface)

42

pre

111.2

Right ovary (6 cm): cystic endometriosis

57

post

23.6

Right ovary (7 cm): mucinous cystadenoma

(n=1)
008

Right ovary (5 cm): serous cystadenoma

(n=1)
009
(n=2)
010

Left ovary (2.1 cm): no histopathologic abnormality
47

pre

48.1

(n=2)
011

Right ovary (7.6 cm): epidermoid cyst
Left ovary: epidermoid cyst

53

post

84

Right ovary (5.2 cm): cystic atretic follicles

(n=1)

66

Left ovary (3.7 cm): benign simple cyst, focal
endometriosis
012

43

post

N/A

Left ovary: cyst (ruptured)

49

pre

28.7

Right ovary (2.2 cm): complex cyst

(n=1)
013
(n=2)
014

Left ovary: complex cyst
68

post

845.2

(n=2)
015

Right ovary (10 cm): high-grade serous carcinoma
Left ovary (10 cm): high-grade serous carcinoma

34

pre

11.3

Right ovary (6 cm): mature teratoma (dermoid cyst)

60

post

161.3

Right ovary (5.5 cm): high-grade serous carcinoma

(n=1)
016
(n=2)

Left ovary (2.8 cm): high-grade serous carcinoma

3.3 Photoacoustic Image Processing and Ovarian Cancer
Diagnosis
With our customized system, we can save co-registered US and PAT images. The spread of the
PAT signals overlay on top of the US image provides useful information regarding ovarian cancer
diagnosis. However, the reconstructed PAT/US images only display normalized amplitude; there
are other information we can extract from the raw or beamformed signals, which can be used to
make a better judgment regarding ovarian tumor. After building a robust system, we focused on
extracting useful features for the automatic diagnosis of ovarian tumors. From US and PAT images
of 16 patients, we have extracted a total of 7 features which is then used statistically analyzed to
get the significance of these features in benign and malignant tumor classification. Logistic
regression classifier was trained to check the automatic diagnosis of the tumors.
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Figure 3. 9 Images in a 63-year-old woman after menopause who had a solid right adnexal mass measuring up to 4.5 cm, ascites, and a thickened endometrium at
contrast-enhanced CT (patient 3). A. Contrast-enhanced CT image. Pathologic findings included a 5-cm ovary (arrow) with well-differentiated stage II endometrioid
adenocarcinoma and an incidental 2.2-cm benign steroid cell tumor. B. US image (EC-12R; Alpinion Medical Systems) of the right adnexa (arrows). C. The
coregistered US and photoacoustic tomography shown in color, with extensive diffused vascular distribution covering a large area of the region of interest in the
depth range of 1–4 cm of a malignant tumor. D. US Doppler image (Logiq 8S; GE Healthcare) of the right adnexa shows a hypoechoic soft tissue mass with
minimal peripheral flow on color Doppler images (arrows). E. CD31 immunostaining in the suture area, showing numerous and extensive microvessels; F.
Coregistered US and photoacoustic tomography of benign tumor shows scattered photoacoustic tomography signals. G. US image of the left ovary (arrows). H.
CD31 immunostaining of surgical sample histopathologic abnormalities.
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3.3.1 Feature Detection and Classification
Independent Area Selection
For each patient, we have collected several sets of data from each view of the ovary. Before
extracting features, it is necessary to find independent frames to avoid duplicating features. To
select independent frames only for avoiding correlated features and potentially biased
classification, the 2-D cross-correlation of the US images was measured between two data sets.
Before applying the cross-correlation operator, both images were normalized within their range to
avoid intensity mismatch. Finally, a hierarchical clustering method was applied to make two
clusters (dependent frames and independent frames) [24]. Hierarchical clustering generates a
dendrogram based on the feature distance among the samples. Dendrogam is a tree diagram used
in higherarchical clustering to demonstrate the relationship between the samples to be clustered.
Samples, which have lower distances according to their features, are placed close in the
dendrogram, and higher distance samples are set far away. The height of their connected branches
is also varied according to their feature distance. The dendrogram was then cut automatically to
obtain two clusters using a threshold on 50% of the maximum distance. Dendrogram of a patient
data is given in Figure 3.10. This figure shows two clusters connected with a blue line. The distance
between these two clusters are maximum. One cluster has a high cross-correlation coefficient,
which are dependent frames and other with low cross-correlation coefficient is considered as
independent frames. Features from all dependent frames were averaged, and one feature from
each independent area was introduced to the classifier. A total of 20 independent benign frames
and 17 independent malignant frames from all patient data were included for classification. Flow
chart of the independent area selection algorithm is presented in Figure 3.11.
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Figure 3. 10 Dendogram for applying hierarchical classifier for independent frame selection

Figure 3. 11 Block diagram for independent frame selection algorithm
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Feature Extraction
Three spectral features from PAT data (maximum SS, MBF and MHz intercept) and three spectral
features from US data (maximum SS, MBF, and 0 MHz intercept) were quantitatively extracted.
PAT spectral features such as SS, MBF, and 0 MHz intercept are related to the absorber's size and
concentration and the spectral features from US signals are connected to the scatterer size,
concentration and acoustic impedance [25] [26]. Menopausal condition of the patient (i.e. premenopausal or post-menopausal) was not considered to be a significant feature, as both pre and
post-menopausal malignancies were reported in the current study (Table 1).
For calculating spectral features, an angular window was applied on the beam data to separate the
region of interest (ROI) from the rest of the tissue. A Hamming window was applied on the
truncated data to minimize the side lobes. The power spectrum of each beam was then calculated
using a fast Fourier Transform (FFT). Any beam lower than 10 dB of the maximum beam data
were discarded to reduce the effect of noise. The Power spectrum of the beams inside the ROI was
normalized by the power spectrum of a known phantom at different depths (250 µm black thread
for PAT and a planar reflector for the US) [21][27]. The approximate point-like target characterizes
the frequency response of the transducer and the electric receiving system. Finally, a line was fitted
to the average normalized spectrum within 80% bandwidth of the transducer's central frequency
(6 MHz). From the fitted line, maximum SS, MBF and 0-MHz intercept were measured. Similar
spectral information (maximum SS, MBF and 0-MHz intercept) is also extracted from US beam
data. As the PAT spectral features for all four wavelengths were highly correlated, hence only one
wavelength (780 nm) features were used for classification purpose.
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Figure 3. 12 (a) In vivo coregistered PAT/US image of the patient with an endometrioid adenocarcinoma of right
ovary marked by ROI. (b) In vivo coregistered PAT/US image of the same patient with a normal left ovary marked
by ROI. In (a) and (b), the angular ROI defines the region where the beam spectrum feature is extracted. (c) The
spectrum (blue) and linear fitting (red) of PAT beam as well extracted parameters from (a). (d) The spectrum (blue)
and linear fitting (red) of PAT beam as well as extracted spectral parameters from (b). (e) The spectrum (blue) and
linear fitting (red) of US beam as well as extracted spectrum parameters from (a). (f) The spectrum and linear fitting
of US beam as well as extracted spectrum parameters from (b).

Feature Selection
Some dependent features have been excluded for training and testing to avoid training with nonsignificant features. The Spearman's rank correlation coefficient (ρ) between two features was
determined to measure their dependencies, and excluded the features with |𝜌| > 0.5 . Seven
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features (3 PAT features, 3 US features, and CA-125) were initially calculated and based on the
correlation coefficient, three features (PAT 0-MHz intercept, US midband fit and US maximum
spectral slope) were excluded. The remaining four significant features were used for training and
testing of a logistic classifier model. Table 3.2 is showing the correlation between the two pairs of
features.
Table 3. 2 Cross-correlation between features

Max.
PAT SS
Maximum
PAT SS
PAT 0-MHz
intercept

1

PAT 0-MHz
intercept

PAT
MBF

Max.
US SS

US 0-MHz
intercept

US
MBF

-0.65

0.201

-0.061

0.029

-0.091

0.546

0.284

-0.282

0.202

0.122

-0.129

0.006

-0.908

0.804

1

1

PAT MBF

1

Max. US SS
US 0-MHz
intercept

1 -0.785
1

US MBF

Classification
A logistic regression model is a widely used binary classifier, which can describe the relationship
between several predictor variables X1, X2,… Xn and dichotomous response variable Y (0 for
benign/normal and 1 for malignant). In this study, a logistic model was used for classification of
benign/normal and malignant ovaries, using PAT and US features as well as CA-125 level. The
logistic model was trained using the GLMFIT function in MATLAB, and the coefficients obtained
from the trained model was used for testing using GLMVAL function. The accuracy of both the
training and testing models were evaluated for sensitivity, specificity, positive predictive value
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(PPV), negative predictive value (NPV) as well as the area under the receiver operating
characteristics (ROC) curve (AUC).
Table 3. 3 Mean value of features and their t-test p values

Mean value
Feature name

(malignant
n=17)

Mean value

p

(benign n=20)

value

Maximum spectral slope (PAT)
1.06±1.49

0.61±1.47

0.378

PAT 0-MHz intercept (dB)

-19.16±5.39

-16.56±5.39

0.164

PAT mid-band fit (dB)

-20.36±10.32

-19.48±6.5

0.771

Maximum spectral slope (US) (dB/MHz)

-0.34±2.25

-0.46±1.77

0.853

US 0-MHz intercept (dB)

11.16±9.97

13.82±7.03

0.379

US mid-band fit (dB)

-4.75±2.81

-4.55±2.65

0.834

634.55±1003.17

48.53±35.55

0.033

(dB/MHz)

CA-125 (units/ml)

ROC curve was calculated by varying the threshold from 0 to 1 at 0.01 interval [28]. For each
threshold, sensitivity, specificity, PPV and NPV were recorded by selecting the training and testing
samples 20 times. For each iteration, 20 (13 benign and 12 malignant) samples were randomly
selected for training and the rest for testing. Average of these 20 iterations provide one sensitivity
and specificity; we obtained 101 sensitivity and specificity from 101 thresholds. This set of
sensitivity and specificity was finally used for obtaining the ROC curve for each model. We
obtained 101 AUC values (each AUC value was the average of 20 AUC values from different
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sample combinations for training and testing) for each threshold using the "perfcurve” function
from MATLAB (2015a).

3.3.2 Results
Table 3.3 shows the mean and standard deviation of features extracted from benign/normal group
and invasive epithelial ovarian cancer group and their p values. Figure 3.13 shows the box plots
of four features of CA-125, PAT midband fit, US 0-MHZ intercept, PAT maximum spectral slope.
Correlated features as given in Table 3.2 were not included in the box plots. Figure 3.14 shows
the AUC for the combination of most significant two PAT features, one US feature and CA-125
for randomly selected testing data.

(a)

P=0.033

(b)

P=0.378

(c)

P=0.771

(d)

P=0.379

Figure 3. 13 Boxplot with p-values for selected four features
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Figure 3. 14 ROC for testing logistic regression model with four features (2 PAT, 1 US and CA125)

3.4 Co-registered Doppler for Improving Region of Interest
Selection of Photoacoustic Imaging
Although this system provides distinguishable PAT images and features for benign and malignant
tumors, during in-vivo studies, some ovaries are difficult to identify and PAT signal origin is
unclear due to the presence of large blood vessels near the target location. The celiac artery carries
a large amount of blood and often shows up near the ovary. Figure 3.15 shows a co-registered USPAT image of a benign ovary marked by the circle. However, strong PAT signals (overlays in red
on top of grey US images) are coming from the side and bottom of the ovary. For this type of
image, it is difficult to select the region of interest (ROI) for PAT data analysis. In this work, we

76

have provided a solution for this problem by reconstructing the Doppler images using the coregistered US data. Since the Doppler signal is only coming from the large blood vessels, using
high US frame rate (1200 Hz), we can identify PAT signals coming from the blood vessels.
Finding of a phantom study is presented here to prove the efficacy of this technique.

Ovary

Blood Vessel

Figure 3. 15 PAT Signal coming from surrounding the blood vessel

3.4.1 Experimental Setup
For demonstrating the performance of the proposed solution, we have used a silicon phantom with
an absorption coefficient of 0.2 cm-1 to emulate a malignant ovary. Indian ink was used to add the
absorption to the phantom, and the amount was controlled to obtain the desired absorption
coefficient. Details phantom fabrication procedure can be found in [29]. Blood mimicking fluid
was created by mixing 1.7x104 cm-3 30 µm glass spheres (Model 3000E, Poterrs Industries LLC,
Valley Forge, PA, USA ) with water and glycol mixer with a specific gravity of 1.043 g/cm3. A
small amount of Indian ink was mixed with this solution to add absorption. US scattering was
coming from the glass spheres, and Indian ink provides the PAT absorption as was expected in
blood. This mixed fluid was then pass through a transparent polyethylene tube of inner diameter
of 500 µm. A variable speed peristaltic pump (Masterflex, Cole-Parmer, Vernon Hills, IL, USA)
was used to pump the blood mimicking fluid through the polyethylene tube. Ovary mimicking
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phantom was attached on top of the tube during the experiment. The schematic of the experiment

Polyethylene Tube

Water

Blood Phantom

5 mm

is given in Figure 3.16.

Solid
Phantom

Water Tank

Pump

Reservoir

Figure 3. 16 Schematic of the experimental setup

3.4.2 Doppler Image Reconstruction
The flow velocity of the blood mimicking fluid through the tube was calculated by estimating the
phase difference between two consecutive frames. Ideally, only two frames are enough to obtain
US Doppler images. However, in practice, it is not feasible. We have saved 12 frames for each
Doppler frame estimation. During the experiment, RF data of one PAT frame and 12 ultrasound
frames are saved for each location. US data was saved at 1200 frames per second. This frame rate
is fast enough to estimate the velocity of ±16 cm/s. Though celiac artery can have blood flow at
around 40 cm/s, we keep this low velocity because of the speed limit of the pump. These channel
data are used to estimate US envelope data for these US frames. Finally, the phase map is estimated
using the cross-correlation method to obtain Doppler images after delay line cancellation. This
delay line canceller discarded the signal coming from the stationary or slow moving artery wall
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movement, which provides a strong reflection in US images. 2nd order Butterworth IIR filter was
used to implement the delay line canceller. Block diagram of the Doppler flow reconstruction is
presented in Figure 3.17.

Cos(2πf0t)
LPF

Transducer

ADC

Channel
Data
LPF

Inphase
Envelope

DLC

Quadrature
Envelope

DLC

Velocity
Estimator

Sin(2πf0t)

System

Software
Figure 3. 17 Doppler image reconstruction flow

3.4.3 Results
To validate the Doppler algorithm, we have passed the blood mimicking fluid through the
polyethylene tube at various speed from 6 cm/s to 14 cm/s at 1 cm/s interval using the pump. The
actual average speed of the fluid was recorded using the power Doppler mode of the ultrasound
system. The average velocity was also calculated from the reconstructed flow map. Figure 3.18
shows the comparison between estimated velocity from the Doppler images and original velocity
set by the pump. In the test setup described above, the silicon phantom works as a stationary
absorber and the tube full of blood mimicking fluid works as a blood vessel. PAT signal is
originated from both stationary phantom and fluid, but the Doppler signal is only coming from the
fluid mixer. Thus, comparing both we can conveniently locate the ovary location and select our
region of interest as demonstrated in Figure 3.19.
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Figure 3. 18 Velocity comparison between true velocity and estimated velocity

Co-registered US/PAT Image

US Doppler Image

US Doppler US Doppler
Co-registeredCo-registered
US/PAT
US/PAT
Figure 3. 19 Doppler assisted ROI selection for coregistered US/PAT
image

d US/PAT

3.5 Summary

US Doppler

Co-registered US/PAT

This chapter described the technology developments that I have accomplished in the field of
photoacoustic tomography during my Ph.D. research. Developing a robust and stable system for
PAT application in the clinical setting was a big challenge for advancing this technology. This has
been done by customizing a commercial ultrasound system. The custom designed control software
was able to coordinate several systems for obtaining the most stable outcome during in-vivo and

80

ex-vivo study. This system has created the opportunity to study the performance of PAT not only
for ovarian cancer diagnosis but also for other organs (colon, rectum, cervix, etc) [30].
After developing the system, a pilot study with 16 ovarian tumor patients was performed using
this system. Reconstructed images and extracted features show significant difference thus validates
the performance of this system. Though the reported features in this dissertation do not show the
best statistical significance, further improvement has been achieved by using better calibration
method. One practical problem related to PAT feature extraction was improved by using coregistered US Doppler information. Necessary software modifications were done to automatic scan
and store multiple modality data during the study. This automatic storage capability made the
system very easy to use in clinical settings. US Doppler image reconstruction will be extended in
the future for PAT Doppler reconstruction which will provide additional information (oxygen
consumption [31]) regarding ovarian cancer detection.
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4 Summary
4.1 Summary
The goal of this research was to improve the design of optical imaging technologies for cancer
monitoring and diagnosis. Improvement has been achieved in both system design and algorithm
development, making diffuse optical tomography and photoacoustic tomography potentially more
user-friendly and suitable for clinical use.
To improve diffuse optical tomography, several system-level designs were altered to reduce the
cost and space required by the previous design. These modifications also improved system control,
which enhanced system performance and user-friendliness. Implementing advanced interference
reduction techniques enabled the same system performance as before, even after different
components were closely spaced for compactness. Homemade electronics not only reduced the
cost of the system development but also accommodated other requirements necessary for
achieving a compact system. The FPGA firmware of the data acquisition board and computer
software was modified to allow controlling the system through a single computer interface.
Optical image reconstruction in diffuse optical tomography is dependent on tumor size and
location measurements from the co-registered ultrasound images, which used to extract manually.
This manual procedure was replaced with a semi-automatic image segmentation algorithm. This
simple and light computation algorithm can provide accurate tumor size and location information
with minimum user input, thus reconstructing the optical images faster. The algorithm also
estimates the chest wall depth, which can be used in further improving the absorption coefficient
estimation.

85

All these improvements make diffuse optical tomography a more useful tool for breast cancer
diagnosis and monitoring. Benefitting from the new improvements in user-friendliness, clinicians
themselves can now directly reconstruct co-registered images, which was impossible with the
previous versions. Once validated in large clinical trials and further improved, this technology will
help to reduce unnecessary biopsies and provide for treatment monitoring in the near future.
In this work, a new version of photoacoustic tomography system was developed to improve
ovarian cancer diagnosis in patients with ovarian abnormalities. The previous version
demonstrated considerable potential by providing encouraging results from ex-vivo studies and a
very limited number of in-vivo samples. However, that system’s performance deteriorated over
time and made it unusable for clinical trials. We proceeded to customize a commercial ultrasound
system for photoacoustic applications; indeed, half of this Ph.D. research focused on system and
data processing improvements for photoacoustic tomography. Python scripts were written to save
co-registered US/PAT image and data from a customized commercial ultrasound system.
Intuitively interfaced control software was developed to co-ordinate the functionalities of the US
system, laser system, and ex-vivo sample holder. A customized probe holder was designed to
accommodate optical fibers to illuminate the target and US transducers to record PAT signals. This
system is easy to use and saves data and images for offline processing.
Data and images saved by the system were later processed to extract useful features for the
automatic diagnosis of benign and malignant ovarian cancers. A robust classifier was obtained
from several features extracted mainly from the saved RF data and combined with pathological
information (CA-125). Promising results were obtained from the first 16 patient’s data of a trial of
total 40 patients.
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4.2 Future Work
Several improvements have been achieved to make diffuse optical tomography and photoacoustic
tomography more accessible for full clinical use. However, in the course of the clinical trials, we
identified opportunities for future improvements.
In the diffuse optical tomography system, the control software does not receive any feedback
regarding hardware states, e.g., the status of the laser light or PMT gain. Such hardware feedback
is essential for the safe operation of the system, because the protocol requires that the laser light
be turned on only when the probe is placed on the breast. However, a crash makes the software
lose all track of the laser light’s state, after which bad data could be collected or the light could
remain on after the probe is removed from the breast. Because of the lack of hardware feedback,
it also may be possible to turn off the system when the PMT gain is on, or when the laser light is
turned on. Both actions are harmful to these expensive components. In the future, a firmware
update will provide hardware feedback for safe operation.
Improvements are also required in the semi-automated segmentation algorithm. Although this
algorithm works well for the available set of ultrasound breast tumor images, it may fail to
correctly identify the tumor area for some complex cases. Because breast tumors can take any
shape and size, conventional image segmentation may not be very successful in collecting tumor
size and location information. Work is going on to apply machine learning to identify hidden
patterns and thus to segment the tumor from the background with better accuracy. Applying
machine learning will also make the algorithm fully-automated, and thus more user-friendly.
In the photoacoustic realm, PAT Doppler information will be collected using high-frequency laser
pulses. This information will enable us to estimate the oxygen consumption in the tumor area,
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which will be a diagnostic advantage because aggressive cancer cells require more oxygen than
benign tumors. Therefore, high oxygen consumption in the tumor region will provide a good
indication of tumor malignancy. Necessary software modifications have already made for data
collection. Soon, the reconstruction algorithm will be ready for PAT Doppler estimation. Other
features will be improved by using a better reference object to get better separation from the trained
classifier. The resulting automated cancer diagnosis will assist radiologists in better detecting
ovarian cancer.
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